



nDatalyze Corp.
(formerly MedXtractor Corp.)
Interim Condensed Consolidated Financial Statements
expressed in Canadian dollars

For the Nine months ended November 30, 2022
(unaudited)

NOTICE OF NO AUDITORS' REVIEW OF INTERIM FINANCIAL STATEMENTS

The accompanying unaudited interim condensed consolidated financial statements of nDatalyze Corp. have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements.

Calgary, Alberta
January 26, 2023

nDatalyze Corp.
(formerly MedXtractor Corp.)

Interim Condensed Consolidated Statement of Financial Position
expressed in Canadian dollars
(unaudited)

As at

	November 30, 2022	February 28, 2022
Assets		(Audited)
Current		
Cash	\$ 981,292	\$ 1,595,385
Accounts receivable	41,061	17,992
Inventory (Note 5)	29,599	67,156
Prepaid expenses and deposits	6,558	10,351
	1,058,510	1,690,884
Non-current Assets		
Furniture and Equipment, net of accumulated amortization	986	1,910
Intangibles (Note 6)	21,514	17,927
Total assets	\$ 1,081,010	\$ 1,710,721
Liabilities		
Current		
Accounts payable and accruals	\$ 12,456	\$ 81,416
Total liabilities	12,456	81,416
Shareholders' Equity		
Share capital (Note 7)	\$ 2,451,048	\$ 2,268,254
Warrants (Note 8)	79,695	706,793
Contributed surplus	1,439,669	819,827
Deficit	(2,901,858)	(2,165,569)
Total shareholders' equity	1,068,554	1,629,305
	\$ 1,081,010	\$ 1,710,721

Approved on behalf of the Board of Directors

Jim Durward

Director

S. Price

Director

The accompanying notes are an integral part of these financial statements

nDatalyze Corp.
(formerly MedXtractor Corp.)
**Interim Condensed Consolidated Statement of Loss
and Comprehensive Loss**
expressed in Canadian dollars
*For the three and nine months ended
(unaudited)*

	3 Months Ended November 30, 2022	3 Months Ended November 30, 2021	9 Months Ended November 30, 2022	9 Months Ended November 30, 2021
Revenues				
Sales (Note 11)	\$ 37,510	\$ 99,495	\$ 134,529	\$ 356,453
Cost of Sales	17,825	43,699	72,042	164,891
Gross margin	\$ 19,685	\$ 55,796	\$ 62,487	\$ 191,562
Expenses				
Depreciation and amortization	\$ 598	\$ 415	\$ 1,732	\$ 1,168
Inventory impairment (Note 5)	40,000	-	40,000	-
Advertising and promotion	82,367	9,289	177,646	29,408
Warranty	-	359	972	1,937
Interest and bank charges	372	(366)	1,885	4,271
Contractors	21,870	17,500	47,870	49,500
Legal, audit, and professional	11,860	7,992	39,341	60,912
Travel, meals and entertainment	2,061	2,909	12,323	5,954
Research and development	16,466	(20)	225,011	2,443
Insurance	1,784	-	5,366	4,149
Investor relations	68,370	54,697	236,915	179,298
Office expenses	674	1,064	7,633	2,849
Accounting	3,000	1,800	7,000	5,400
Rent	2,100	2,800	6,300	6,990
Utilities	262	199	767	606
Stock based compensation	-	-	-	48,507
Total expenses	\$ 251,784	\$ 98,638	\$ 810,761	\$ 403,392
Other Income				
Foreign exchange gain (loss)	\$ -	\$ (278)	\$ 231	\$ 122
Interest Income	6,022	1,415	11,754	5,383
Total other income	\$ 6,022	\$ 1,137	\$ 11,985	\$ 5,505
Net operating loss and comprehensive loss	\$ (226,077)	\$ (41,705)	\$ (736,289)	\$ (206,325)
Loss per share (basic and diluted)	\$ (0.01)	\$ (0.00)	\$ (0.02)	\$ (0.01)
Weighted average shares outstanding (basic and diluted)	38,712,425	36,921,425	\$ 38,712,425	\$ 35,885,691

The accompanying notes are an integral part of these financial statements

nDatalyze Corp.
(formerly MedXtractor Corp.)

Interim Condensed Consolidated Statement of Changes in Shareholders' Equity
expressed in Canadian dollars

For the three and nine months ended November 30, 2022
(unaudited)

	Share Capital (\$)	Warrants (\$)	Contributed Surplus (\$)	Deficit (\$)	Shareholders' Equity (\$)
As at February 28, 2021	1,021,847	-	771,320	(992,088)	801,079
Shares issued for cash	1,815,000	-	-	-	1,815,000
Fair value of warrants	(580,145)	580,145	-	-	-
Share issue costs	(147,522)	35,722	-	-	(111,800)
Stock based compensation	-	-	48,507	-	48,507
Net loss	-	-	-	(206,325)	(206,325)
As at November 30, 2021	2,109,180	615,867	819,827	(1,98,413)	2,346,461
As at February 28, 2022	2,268,254	706,793	819,827	(2,165,569)	1,629,305
Shares issued for cash	133,500	-	-	-	133,500
Warrants exercised	87,895	(36,492)	-	-	51,403
Warrants expired	-	(619,842)	619,842	-	-
Fair value of warrants	(26,236)	26,236	-	-	-
Share issue costs	(12,365)	3,000	-	-	(9,365)
Net loss	-	-	-	(736,289)	(736,289)
As at November 30, 2022	2,451,048	79,695	1,439,669	(2,901,858)	1,068,554

The accompanying notes are an integral part of these financial statements

nDatalyze Corp.
(formerly MedXtractor Corp.)
Interim Condensed Consolidated Statement of Cash Flows
expressed in Canadian dollars
For the nine months ended
(unaudited)

Cash provided by (used in):

	November 30, 2022	November 30, 2021
Operating activities		
Net loss	\$ (736,289)	\$ (206,325)
Depreciation and amortization	1,732	1,168
Stock based compensation	-	48,507
Change in non-cash working capital (Note 12)	(50,678)	(74,184)
Cash flows used in operating activities	\$ (785,235)	\$ (230,834)
Investing activities		
Purchase of furniture and equipment	\$ -	\$ (1,321)
Investment in intangibles (Note 6)	(4,396)	(742,533)
Cash flows used in investing activities	(4,396)	(743,854)
Financing activities		
Issuance of common share and warrants, net of costs	175,538	1,703,200
Cash flows from financing activities	175,538	1,703,200
Increase (decrease) in cash	(614,093)	728,512
Cash, beginning of period	1,595,385	781,393
Cash, end of period	\$ 981,292	\$ 1,509,905

The accompanying notes are an integral part of these financial statements

nDatalyze Corp.
(formerly MedXtractor Corp.)
**Notes to the Interim Condensed
Consolidated Financial Statements**
expressed in Canadian dollars
For the nine months ended November 30, 2022
(unaudited)

1. Incorporation and operations

nDatalyze Corp. (formerly MedXtractor Corp.) the "Company") was incorporated on January 24, 2018 by Certificate of Incorporation issued pursuant to the provisions of the Business Corporations Act (Alberta). On October 22, 2021 the Company changed its name to nDatalyze Corp.

The Company generates technologically-based solutions focusing on applying machine learning to predict potential mental conditions within the consumer mental health sector and is developing a data driven consumer mHealth application. The Company also manufactures and sells essential oil CO2 extraction equipment. The Company is publicly trading and listed on the Canadian Securities Exchange (CSE:NDAT) (OTC:NDATF).

On July 13, 2020, the Company incorporated a wholly-owned subsidiary 2273670 Alberta Ltd. for manufacturing alcohol-based extractors. The head office and registered office of the Company is located at Suite 1150, 707 – 7th Ave. SW Calgary, Alberta T2P 3H6.

2. Basis of preparation

Statement of compliance

These financial statements for the nine months ended November 30, 2022 are unaudited and have been prepared in accordance with IAS 34 Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC") in effect for the period ending November 30, 2022. These interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ending February 28, 2022.

These financial statements were authorized for issue in accordance with a resolution of the directors on January 26, 2023.

Going Concern

These financial statements have been prepared on a going concern basis, which assumes that the Company will continue to operate for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

The financial statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. Consequently, adjustments would then be necessary to the carrying value of assets and liabilities, the reported revenues and expenses and their classifications. Such adjustments, if required, could be material.

Basis of measurement

These financial statements are stated in Canadian dollars which is the Company's functional currency and are prepared on a going concern basis, under the historical cost convention.

Use of estimates and judgements

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of the amount, event or actions, actual results ultimately may differ from those estimates. Areas where estimates are significant to the financial statements are disclosed in Note 4.

nDatalyze Corp.
(formerly MedXtractor Corp.)
**Notes to the Interim Condensed
Consolidated Financial Statements**
expressed in Canadian dollars
For the nine months ended November 30, 2022
(unaudited)

Basis of consolidation

These consolidated financial statements include the accounts of nDatalyze Corp. (formerly MedXtractor Corp.) and its wholly owned subsidiary, 2273670 Alberta Ltd. The subsidiary is fully consolidated from the date of acquisition, being the date of which the Company obtained control, and continues to be consolidated until such control ceases. The financial statements of the subsidiary are prepared for the same reporting period as the parent, using consistent accounting policies. Any balances, unrealized gains or losses, or income and expenses from intra-company transactions are fully eliminated upon consolidation.

3. Significant accounting policies

Accounting policies as described in the audited financial statements and the notes thereto for the year ended February 28, 2022.

4. Significant accounting estimates and assumptions

The preparation of the financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and judgments are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual outcomes can differ from these estimates.

Estimates

The key sources of estimation uncertainty that have a significant risk of causing material adjustment to the amounts recognized in the financial statements are:

Fair value of financial instruments

The estimated fair value of financial assets and liabilities, by their very nature, are subject to measurement uncertainty.

Taxes

Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.

Stock based payment transactions

The Company measures the cost of equity-settled share-based transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the share option, volatility, forfeiture rate, risk-free rate and dividend yield and making assumptions about them.

nDatalyze Corp.
(formerly MedXtractor Corp.)
**Notes to the Interim Condensed
Consolidated Financial Statements**
expressed in Canadian dollars
For the nine months ended November 30, 2022
(unaudited)

Judgements

The key areas of judgment that have a significant risk of causing material adjustment to the amounts recognized in the financial statements are:

Impairment of non-financial assets

The determination of whether indicators of impairment exist and the aggregation of assets into cash-generating units (“CGU’s”) based on their ability to generate independent cash flows are subject to management’s judgment. The recoverable amounts used for impairment calculations require estimates of future cash flows related to the assets or CGU’s and estimates of discount rates applied to these cash flows.

Taxes

The Company recognizes deferred tax assets to the extent that it is probable that future taxable profits will be available to utilize the Company’s deductible temporary differences which are based on management’s judgement on the degree of future taxable profits. To the extent that future taxable profits differ significantly from the estimates impacts the amount of the deferred tax assets management judges is probable.

Financial instruments

The Company is required to classify its various financial instruments into certain categories for the financial instruments’ initial and subsequent measurement. This classification is based on management’s judgement as to the purpose of the financial instrument and to which category is most applicable.

5. Inventory

Inventory consists of:	November 30, 2022	February 28, 2022
Raw Material	\$ 67,244	\$ 58,664
Sub Assembly	2,355	8,492
Inventory impairment reserve	(40,000)	-
Total	\$ 29,599	\$ 67,156

During the nine months ended November 30, 2022, the Company expensed \$46,471 (September 30, 2021 - \$106,529) of inventory which is included in cost of sales. During the quarter ended November 30, 2022 the Company recognized a \$40,000 impairment reserve associated with the corporate focus on mental health operations and reduced emphasis on development of manufacturing and sales of essential oil CO2 extraction equipment.

Intangibles assets

	November 30, 2022	February 28, 2022
Intangible assets, cost	23,667	19,176
Accumulated amortization	(2,153)	(1,249)
Intangible assets, net of accumulated amortization	\$ 21,514	\$ 17,927

On February 22, 2018, the Company acquired intangible assets including Canadian and US patents, URL website address, and all intellectual rights relating to the cannabis oil extraction technology.

nDatalyze Corp.
(formerly MedXtractor Corp.)
**Notes to the Interim Condensed
Consolidated Financial Statements**
expressed in Canadian dollars
For the nine months ended November 30, 2022
(unaudited)

6. Share capital

Authorized:

Unlimited number of voting Common Shares without par value
Unlimited number of non-voting Preferred shares issuable in series without par value

Issued: Common Shares

	Number of Shares	\$
As at February 28, 2022	37,921,425	2,268,254
Shares issued in private placement	534,000	107,264
Share issue costs		(12,365)
Finders fees warrants exercised	257,000	87,895
As at November 30, 2022	38,712,425	2,451,048

A private placement of 534,000 units was completed on March 21, 2022, at a price of \$0.25 per unit for gross proceeds of \$133,500 with finder fees share issue costs of \$9,365. Each unit consists of one common share and one common share purchase warrant entitling the holder to acquire one common share at a price of \$0.35 per common share for a period of 12 months, subject to the accelerated expiry provision where if, on any 10 consecutive trading days occurring after September 22, 2022, the closing sales price of the common shares (or the closing bid, if no sales were reported on a trading day) as quoted on the Canadian Securities Exchange is greater than \$0.60 per common share, the Company may provide notice in writing to the holders of the warrants by issuance of a press release that the expiry date of the warrants will be accelerated to the 30th day after the date on which the Company issues such press release. The Company paid eligible finders aggregate cash finders fees of \$9,365 and issued 37,380 finders warrants to purchase common shares of the Company at a price of \$0.25 per common share for a period of 12 months with a value of \$3,000 (Note 8).

7. Warrants

Warrants	Number of warrants outstanding	Value	Average Exercise price	Weighted average life (in years)
As at February 28, 2022	10,633,000	\$ 706,793	\$0.34	0.13
Warrants exercised	(257,000)	\$(36,492)	\$0.20	
Warrants expired unexercised	(9,376,000)	(619,842)	\$0.35	
Warrants issued	534,000	26,236	\$0.35	0.21
Finders fees warrants issued	37,380	3,000	\$0.25	0.30
As at November 30, 2022	1,571,380	\$79,695	\$0.35	0.24

On March 14, 2022, 257,000 finders fee warrants were exercised at a price of \$0.20 per warrant for gross proceeds of \$51,400.

nDatalyze Corp.
(formerly MedXtractor Corp.)
**Notes to the Interim Condensed
Consolidated Financial Statements**
expressed in Canadian dollars
For the nine months ended November 30, 2022
(unaudited)

534,000 warrants issued exercisable at a price of \$0.35 per share, expire in one year with a fair value of the \$26,236 or \$0.05 per warrant calculated using the Black-Scholes option pricing model. The assumptions for this calculation were a risk free interest rate of 1.96%, expected life of 1 year and expected volatility of 95%.

37,380 warrants issued to finders exercisable at a price of \$0.25 per share, expire in one year with a fair value of the \$3,000 or \$0.08 per warrant calculated using the Black-Scholes option pricing model. The assumptions for this calculation were a risk free interest rate of 1.96%, expected life of 1 year and expected volatility of 95%.

9,075,000 warrants with an exercise price of \$0.35 expired unexercised and 301,800 finders fees warrants expired unexercised.

8. Capital disclosures

The Company's capital consists of share capital. The Company's objective for managing capital is to maintain sufficient capital to advance its technology and create operating profits.

The Company sets the amount of capital in relation to risk and manages the capital structure and makes adjustments to it in light of changes to economic conditions and the risk characteristics of the underlying assets.

The Company's objectives when managing capital are:

- i. to maintain a flexible capital structure, which optimizes the cost of capital at acceptable risk; and,
- ii. to maintain investor, creditor and market confidence in order to sustain the future development of the business.

The Company is not subject to any externally or internally imposed capital requirements at period-end.

9. Financial instruments

The Company, as part of its operations, carries financial instruments consisting of cash, accounts receivable, and accounts payable and accruals. It is management's opinion that the Company is not exposed to significant credit, interest, or currency risks arising from these financial instruments except as otherwise disclosed.

Fair value

Fair value represents the price at which a financial instrument could be exchanged in an orderly market, in an arm's length transaction between knowledgeable and willing parties who are under no compulsion to act. The Company classifies the fair value of the financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instrument.

Level 1: Fair value measurements are those derived from quoted prices (unadjusted) in the active market for identical assets or liabilities.

Level 2: Fair value measurements are those derived from inputs other than quoted prices that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (derived from prices).

Level 3: Fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data.

The fair value of cash is determined on level 1 inputs. The carrying amount of cash, accounts receivable, and account payable and accruals approximates its fair value due to the short-term maturities of these items.

nDatalyze Corp.
 (formerly MedXtractor Corp.)
**Notes to the Interim Condensed
 Consolidated Financial Statements**
expressed in Canadian dollars
For the nine months ended November 30, 2022
(unaudited)

Credit Risk

Credit risk is the risk of loss associated with the counterparty's inability to fulfill its payment obligations. The Company believes it has no significant credit risk.

Liquidity Risk

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at November 30, 2022, the Company had a cash balance of \$981,292 to pay liabilities of \$12,456.

Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, and commodity and equity prices.

i. Interest rate risk

The Company has cash balances and no interest-bearing debt.

ii. Foreign currency risk

As at November 30, 2022, the Company had \$13,507 in cash denominated in US Dollars foreign currency.

iii. Commodity risk

The Company is not exposed to commodity price risk.

10. Stock Option Plan

The Company has a stock option plan for its officers, directors, employees and consultants. The maximum number of common shares issuable under the Plan cannot exceed 10% of the Company's issued and outstanding common shares.

Stock Options	Number of options outstanding and exercisable	Weighted average exercise price	Weighted average life (in years)
As at February 28, 2022	3,150,000	\$0.25	4.00
As at November 30, 2022	3,150,000	\$0.25	3.25

11. Segmented Information

Revenues are predominantly to International customers with \$95,445 for the nine months ended November 30, 2022 (November 30, 2021 - \$230,230).

nDatalyze Corp.
 (formerly MedXtractor Corp.)
**Notes to the Interim Condensed
 Consolidated Financial Statements**
expressed in Canadian dollars
For the nine months ended November 30, 2022
(unaudited)

12. Changes in non-cash working capital

	Nine months ended	
	November 30, 2022	November 30, 2021
Accounts receivable	\$ (23,069)	\$ (6,830)
Inventory	37,557	(16,882)
Prepaid expenses and deposits	3,793	2,283
Accounts payable and accruals	(68,960)	(52,755)
Changes in non-cash working capital	\$ (50,679)	\$ (74,184)